Galecto raise US$85m in Nasdaq IPOHBM portfolio company Galecto has raised US$85m through the placement of 5.67 million new shares at a price of US$15 per share at Nasdaq. more ➔
BI initiates Phase II testing of COVID-19...Boehringer Ingelheim announced the start of Phase II studies of its oral TRPC6 blocker code-named BI 764198 in patients hospitalised for COVID-19. more ➔
3P Bio to manufacture SpyBiotech vaccineBritish SpyBiotech has outsourced GMP manufacturing of its VLP vaccine platform to Navarra-based 3P Biopharmaceuticals. more ➔
Bioinvent AB licences BI-1206 to CASI Phar...Swedish BioInvent AB has licensed its anti-Fc?RllB antibody BI-1206 for $95m to CASI Pharmaceuticals for distribtion in the Greater China region more ➔
Transgene reports clinical results of TG40...Transgene SA has reported positive results of an exploratory Phase Ib/II study in HPV-16-positive cancers combining its cancer vaccine TG4001 with Merck KgaA’s PD-L1 blocker avelumab. more ➔
Roche licences antiviral nucleoside from A... Roche AG has paid US$350 in cash to co.develop and market Atea Pharmaceutical’s oral direct-acting antiviral, AT-527, to limit proliferation of SARS-CoV-2. more ➔
ADC company Araris Biotech raises CHF15.2mNew ADC company Araris Biotech has got backing by Pureos Bioventures and co-investors in a CHF15.2m seed round to develop a new class of antibody drug conjugates. · more ➔
Vifor Pharma in US$100m licence deal with...Vifor Pharma and Cara Therapeutics have signed a US license agreement for Korsuva to treat dialysis patients with pruritus. more ➔
Atriva Therapeutics gets €24m from EIB Atriva Therapeutics has secured a €24m loan to push the development of its COVID-19 programme ATR-002, an antiviral, anti-inflammatory MEK inhibitor. more ➔
Topas raises €22m in Series B financinin...Topas Therapeutics GmbH will use the €22m proceeds from a Series B Financing to advance two pipeline candidates. more ➔
